ATE477339T1 - Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung - Google Patents

Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung

Info

Publication number
ATE477339T1
ATE477339T1 AT06742440T AT06742440T ATE477339T1 AT E477339 T1 ATE477339 T1 AT E477339T1 AT 06742440 T AT06742440 T AT 06742440T AT 06742440 T AT06742440 T AT 06742440T AT E477339 T1 ATE477339 T1 AT E477339T1
Authority
AT
Austria
Prior art keywords
compositions
markers
treatment
outcome
predicting
Prior art date
Application number
AT06742440T
Other languages
English (en)
Inventor
Kirsten Nielsen
Bent Eilertsen
Tim Poulsen
Henning Mouridsen
Original Assignee
Dako Denmark As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dako Denmark As filed Critical Dako Denmark As
Application granted granted Critical
Publication of ATE477339T1 publication Critical patent/ATE477339T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Processing Of Solid Wastes (AREA)
AT06742440T 2005-05-31 2006-05-30 Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung ATE477339T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68607005P 2005-05-31 2005-05-31
PCT/DK2006/000300 WO2006128463A2 (en) 2005-05-31 2006-05-30 Compositions and methods for predicting outcome of treatment

Publications (1)

Publication Number Publication Date
ATE477339T1 true ATE477339T1 (de) 2010-08-15

Family

ID=35809661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06742440T ATE477339T1 (de) 2005-05-31 2006-05-30 Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung

Country Status (6)

Country Link
US (1) US8679746B2 (de)
EP (1) EP1885878B1 (de)
AT (1) ATE477339T1 (de)
DE (1) DE602006016106D1 (de)
ES (1) ES2350648T3 (de)
WO (1) WO2006128463A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110318732A1 (en) * 2008-05-28 2011-12-29 Singer Robert H Prediction of chemotherapeutic response via single-cell profiling of transcription site activation
US8583380B2 (en) * 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
JP2012528569A (ja) * 2009-05-29 2012-11-15 ヴェンタナ メディカル システムズ， インク． インサイツハイブリダイゼーションを使用した生物学試料の遺伝子コピー数のスコアリング法
RU2565550C2 (ru) 2010-09-24 2015-10-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Прямой захват, амплификация и секвенирование днк-мишени с использованием иммобилизированных праймеров
US9556473B2 (en) * 2011-02-15 2017-01-31 Leica Biosystems Newcastle Ltd Methods for identifying nucleic acid sequences
KR20170007181A (ko) 2015-07-10 2017-01-18 3스캔 인크. 조직학적 염색제의 공간 다중화

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2279266T3 (es) * 2003-08-28 2007-08-16 F. Hoffmann-La Roche Ag Correlacion del cociente de los niveles de expresion del mrna de la timidina fosforilasa y la dihidropirimidina dehidrogenasa en el cancer colorrectal con supervivencia libre de enfermedad en pacientes tratados con 5-fu.

Also Published As

Publication number Publication date
ES2350648T3 (es) 2011-01-25
US20090042187A1 (en) 2009-02-12
EP1885878A2 (de) 2008-02-13
DE602006016106D1 (de) 2010-09-23
EP1885878B1 (de) 2010-08-11
US8679746B2 (en) 2014-03-25
WO2006128463A2 (en) 2006-12-07
WO2006128463A3 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
EP1945754A4 (de) Zusammensetzungen und verfahren zur behandlung und diagnostizierung von krebs
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
EP1765391A4 (de) Bakterielle zusammensetzungen zur behandlung von krebs
ATE523525T1 (de) Anti-tumorassoziiertes antigen tat10772 zum nachweis und behandlung von krebs
ZA200809250B (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
ZA200702322B (en) Compositions and methods for the diagnosis and treatment of tumor
EP2141989A4 (de) Zusammensetzungen und verfahren zur vorbeugung und behandlung von suchtkrankheiten
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
DE602006012013D1 (de) Proteasom-hemmer und verwendungsverfahren dafür
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
WO2006015079A3 (en) Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
TW200626900A (en) Wnt proteins and detection and treatment of cancer
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
DE602004021435D1 (de) Injizierbare zusammensetzung zur behandlung von krebs
TNSN06321A1 (en) Beta-carbolines useful for treating inflammatory disease
DE602006016106D1 (de) Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
IL185900A0 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1755581A4 (de) Verfahren und zusammensetzungen zur behandlung von myokardialen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties